Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection

Sei Shizuko; Susan L. Sandelli; Georgia Theofan; Silvia Ratto-Kim; Mutsuko Kumagai; Lawrence D. Loomis-Price; Josephine H. Cox; Paul Jarosinski; Claire M. Walsek; Pim Brouwers; David J. Venzon; Jing Xu; Philip A. Pizzo; Ronald B. Moss; Merlin L. Robb; Lauren V. Wood

doi:10.1086/314944

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection

Sei Shizuko, Susan L. Sandelli, Georgia Theofan, Silvia Ratto-Kim, Mutsuko Kumagai, Lawrence D. Loomis-Price, Josephine H. Cox, Paul Jarosinski, Claire M. Walsek, Pim Brouwers, David J. Venzon, Jing Xu, Philip A. Pizzo, Ronald B. Moss, Merlin L. Robb, Lauren V. Wood

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log₁₀ HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n = 4] vs. 2.5 U [n = 3], respectively; P = .034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P < .02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P < .01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.

Original language	English
Pages (from-to)	626-640
Number of pages	15
Journal	Journal of Infectious Diseases
Volume	180
Issue number	3
DOIs	https://doi.org/10.1086/314944
State	Published - 8 Sep 1999

Access to Document

10.1086/314944

Cite this

Shizuko, S., Sandelli, S. L., Theofan, G., Ratto-Kim, S., Kumagai, M., Loomis-Price, L. D., Cox, J. H., Jarosinski, P., Walsek, C. M., Brouwers, P., Venzon, D. J., Xu, J., Pizzo, P. A., Moss, R. B., Robb, M. L., & Wood, L. V. (1999). Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. Journal of Infectious Diseases, 180(3), 626-640. https://doi.org/10.1086/314944

@article{7b2ca057abd940b78f5a0776d5db3c40,

title = "Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection",

abstract = "The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n = 4] vs. 2.5 U [n = 3], respectively; P = .034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P < .02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P < .01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.",

author = "Sei Shizuko and Sandelli, {Susan L.} and Georgia Theofan and Silvia Ratto-Kim and Mutsuko Kumagai and Loomis-Price, {Lawrence D.} and Cox, {Josephine H.} and Paul Jarosinski and Walsek, {Claire M.} and Pim Brouwers and Venzon, {David J.} and Jing Xu and Pizzo, {Philip A.} and Moss, {Ronald B.} and Robb, {Merlin L.} and Wood, {Lauren V.}",

year = "1999",

month = sep,

day = "8",

doi = "10.1086/314944",

language = "English",

volume = "180",

pages = "626--640",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

Shizuko, S, Sandelli, SL, Theofan, G, Ratto-Kim, S, Kumagai, M, Loomis-Price, LD, Cox, JH, Jarosinski, P, Walsek, CM, Brouwers, P, Venzon, DJ, Xu, J, Pizzo, PA, Moss, RB, Robb, ML & Wood, LV 1999, 'Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection', Journal of Infectious Diseases, vol. 180, no. 3, pp. 626-640. https://doi.org/10.1086/314944

TY - JOUR

T1 - Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection

AU - Shizuko, Sei

AU - Sandelli, Susan L.

AU - Theofan, Georgia

AU - Ratto-Kim, Silvia

AU - Kumagai, Mutsuko

AU - Loomis-Price, Lawrence D.

AU - Cox, Josephine H.

AU - Jarosinski, Paul

AU - Walsek, Claire M.

AU - Brouwers, Pim

AU - Venzon, David J.

AU - Xu, Jing

AU - Pizzo, Philip A.

AU - Moss, Ronald B.

AU - Robb, Merlin L.

AU - Wood, Lauren V.

PY - 1999/9/8

Y1 - 1999/9/8

N2 - The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n = 4] vs. 2.5 U [n = 3], respectively; P = .034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P < .02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P < .01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.

AB - The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n = 4] vs. 2.5 U [n = 3], respectively; P = .034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P < .02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P < .01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=0032827133&partnerID=8YFLogxK

U2 - 10.1086/314944

DO - 10.1086/314944

M3 - Article

C2 - 10438349

AN - SCOPUS:0032827133

SN - 0022-1899

VL - 180

SP - 626

EP - 640

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -